【情報源】
Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. [published online ahead of print May 22, 2020]. Lancet. doi:https://doi.org/10.1016/S01406736(20)31208-3
コメントを追加する